All posts by medical

Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more – CNBC

Cases of eggs from Cal-Maine Foods, Inc., await to be handed out by the Mississippi Department of Agriculture and Commerce employees to several hundred families along with over 1,400 boxes of meat products from Merchants Foodservice and 2,200 gallons of milk from Borden Dairy, at the Mississippi State Fairgrounds in Jackson, Miss., Aug. 7, 2020.

Rogelio V. Solis | AP

Check out the companies making headlines after the bell on Tuesday:

Cal-Maine Foods Cal-Maine Foods reported a surprise profit for its fiscal second quarter, sending the stock up more than 2% after-hours trading. The company posted earnings per share of 25 cents on revenue of $347.3 million. Analysts polled by FactSet expected a loss of 8 cents pre share on revenue of $333.5 million. The company's egg-dozen sales grew by 4.6% on a year-over-year basis.

Myriad Genetics Shares of the biotechnology company rose nearly 2% on news Myriad will explore "strategic alternatives" for its autoimmune business. The company is also restructuring its international operations.

Smart Global Holdings Smart Global posted fiscal first-quarter earnings per share that were better than expected, lifting the computer-memory manufacturer's stock up by 2.4%. Smart Global reported adjusted earnings per share of 78 cents, topping a FactSet estimate of 70 cents per share. The company also issued better-than-expected revenue guidance for the current quarter.

Nektar Therapeutics Nektar shares slipped about 1% after the company announced Dr. Brian Kotzin will take over as interim chief medical officer, effective immediately, replacing current CMO Wei Lin.

View post:
Stocks making the biggest moves after the bell: Cal-Maine Foods, Myriad Genetics & more - CNBC

What is Genetic Cancer Testing and How Do Patients Get Tested? – Curetoday.com

At the molecular level all cancers are genetic, they start as your normal breast cell or ovaries and overtime pick up small genetic changes. When talking about inherited testing or hereditary testing only a small portion of cancer can be passed down in a family. We roughly quote 5-10% can be due to hereditary reasons or something we might find in an inherited genetic test, explained Dr. Tong at the CURE Educated Patient Womens Cancer Summit.

Genetic testing is a critical part of understanding these cancers, as well as how to treat, and Ill be discussing today about how we think about how genetics fits in cancer development, how genetic testing plays a role and how genetic counseling can help induvial and families come to decisions around genetics, says Dr. Tong.

Some exceptions include, up to 20% of negative breast cancers that can be hereditary and up to 25% of ovarian cancers can be hereditary, which is why genetic testing is recommended for all ovarian cancers.

When talking about hereditary cancer Dr. Tong says clinicians and genetic counselors are thinking about if that person has a higher chance of developing cancer, because nobody is at a 0% of developing cancer. Genetic testing will look at to see if they can identify what is elevating the persons risk of developing cancer, and can you potentially explain why a person developed certain cancer.

Part of what we learn from genetic testing, is not only could it have been due to a hereditary cause, such as a mutation in a gene, but which gene mutation and how can we differentially take care of people depending on which gene mutation did cause that, says Dr. Tong.

Guidelines recommend that all women diagnosed with epithelial ovarian cancer and breast cancer should be offered genetic testing.

Beginning in 2015 technology has brought three different types of gene testing or as they call it, Multi-Gene Panel Testing. Then there is a decision about how much genetic testing to do. For genes that they know are associated with inherited risk, those are high and moderate risk genes, they have actionable guidelines for treatment, risk reduction or prevention.

As technology develops you think about if the low-risk genes should also be looked at, the most likely have no impact on your health, such as a recessively inherited cancer risk, the information from these genes may be relevant to your family members or future generations. Some panel offers looking at newly described genes, they have limited evidence that they may impact inherited cancer risk, and they dont have actionable guidelines yet but could in the future.

We think that pretest counseling with a genetic counselor can help an induvial better understand how genetics impacts or plays a role in their cancer diagnosis or in their family history. Genetic counselors will take a look at family history and go many generations to look at distant relatives to see if there is a pattern to the cancers of that family that can be inherited, or does it look more like sporadic risks, then that counselor can discuss what the testing options are, how much testing to have or if its even right for you or not, says Dr. Tong about genetic testing counseling.

Types of results include a negative, the most important to be working with a genetic counselor, meaning there was no change found in the gene, it is considered a normal result and cancer treatment, screening and prevention decisions can be based on personal and family history of cancer. The next is a variant or uncertain significance, also considered a normal result, a change was found but is most likely due to normal human variation. The last result is positive result, where they find a change or genetic mutation that is associated with cancer, cancer treatment, screening and prevention decisions will be based on the risks specific to the change found.

Some may fear that they may be discriminated against due to their genetic testing results. There are laws in place that will protect you and your family members from employment or health insurance discrimination such as the Genetic Information Non-Discrimination Act of 2008, or GINA. In addition, there is the Americans with Disabilities Act, ADA, and the Health Information Portability and Accountability Act, HIPPA. However, there are limitations, how these laws dont protect against other types of discrimination such as life insurance, disability or long-term care, which would be discussed in your genetic counseling session.

Genetic testing can help thinking about what the path forward is for you and your family when we do learn the results, Dr. Tong concludes. He says going to a genetic counselor can help medically keep you healthy and also emotionally, connecting you with different resources and support organizations.

See more here:
What is Genetic Cancer Testing and How Do Patients Get Tested? - Curetoday.com

EdUHK Partners with NNU to Conduct Research on Neuroscience and Education Technology in Special Education – QS WOW News

The Integrated Centre for Wellbeing (I-WELL) of The Education University of Hong Kong (EdUHK), in collaboration with Nanjing Normal University of Special Education (NNU), and supported by the Tin Ka Ping Foundation (TKP), conducted research on neuroscience and education technology in special education.

The project was completed in 2020, and a presentation was conducted in November of the same year at the Heep Hong Society.

In the presentation, Professor Leung Chi-hung, Co-Director of I-WELL and Professor (Practice) at the Department of Special Education and Counselling of EdUHK, summarized three stages of professional training to benefit students with autism, hearing impairment or intellectual disabilities in the mainland, especially those living in remote areas.

NNU professors and in-service teachers who participated in the program shared their experience, along with their respective research topics, led by Professor Leung, Dr Liu Duo, Associate Head and Associate Professor at the Department of Special Education and Counselling of EdUHK, and Dr Angus Wang Li-chih, Assistant Professor, at the same department.

The topics covered the areas of music and information science, early childhood education, applied hearing impairment teaching, and sports and rehabilitation.

A special education e-manual, comprising concise knowledge about neuroscience and e-learning, was also developed. This knowledge can be transferred into applied research plans, addressing the learning needs of children with special educational needs in Nanjing. NGOs and special schools in Hong Kong will be invited to download the e-manual, together with the training manual, for reference.

I-WELL recently received another funding grant from TKP for a new engagement, titled Research, Development and Application of Educational Materials on Neuroscience and Education Technology in Special Education, which is a continuation of this project.

With NNU as the same partnering university, the new project will focus on the production of educational materials, training and applications related to neuroscience and education technology in special education to cultivate special education in the mainland.

The rest is here:
EdUHK Partners with NNU to Conduct Research on Neuroscience and Education Technology in Special Education - QS WOW News

New Evidence COVID-19 Invades the Brain – Medscape

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

SARS-CoV-2 can invade the brain and directly act on brain cells, causing neuroinflammation, new animal research suggests.

Investigators injected spike 1 (S1), which is found on the tufts of the "red spikes" of the virus, into mice and found that it crossed the blood-brain barrier (BBB) and was taken up not only by brain regions and the brain space but also by other organs specifically, the lungs, spleen, liver, and kidneys.

"We found that the S1 protein, which is the protein COVID-19 uses to 'grab onto' cells, crosses the BBB and is a good model of what the virus does when it enters the brain," lead author William A. Banks, MD, professor of medicine, the University of Washington School of Medicine, Seattle, Washington, told Medscape Medical News.

"When proteins such as the S1 protein become detached from the virus, they can enter the brain and cause mayhem, causing the brain to release cytokines, which, in turn, cause inflammation and subsequent neurotoxicity," said Banks, who is also associate chief of staff and a researcher at the Puget Sound Veterans Affairs Healthcare System.

The study was published online December 16 in Nature Neuroscience.

COVID-19 is associated with a variety of central nervous system symptoms, including the loss of taste and smell, headaches, confusion, stroke, and cerebral hemorrhage, the investigators note.

Banks explained that SARS-CoV-2 may enter the brain by crossing the BBB, acting directly on the brain centers responsible for other body functions. The respiratory symptoms of COVID-19 may therefore result partly from the invasion of the areas of the brain responsible for respiratory functions, not only from the virus' action at the site of the lungs.

The researchers set out to assess whether a particular viral protein S1, which is a subunit of the viral spike protein could cross the BBB or enter other organs when injected into mice.

They found that when intravenously injected S1 (I-S1) was cleared from the blood, tissues in multiple organs, including the lung, spleen, kidney, and liver, took it up.

Notably, uptake of I-S1 was higher in the liver, "suggesting that this protein is cleared from the blood predominantly by the liver," Banks said. In addition, uptake by the lungs is "important, because that's where many of the effects of the virus are," he added.

The researchers found that I-S1 in the brains of the mice was "mostly degraded" 30 minutes following injection. "This indicates that I-S1 enters the BBB intact but is eventually degraded in the brain," they write.

Moreover, by 30 minutes, more than half of the I-S1 proteins had crossed the capillary wall and had fully entered into the brain parenchymal and interstitial fluid spaces, as well as other regions.

The researchers then induced an inflammatory state in the mice through injection of lipopolysaccharide (LPS) and found that inflammation increased I-S1 uptake in both the brain and the lung (where uptake was increased by 101%).

"These results show that inflammation could increase S1 toxicity for lung tissue by increasing its uptake," the authors suggest. Moreover, inflammation also increased the entry of I-S1 into the brain, "likely due to BBB disruption."

In human beings, male sex and APOE4 genotype are risk factors for both contracting COVID-19 and having a poor outcome, the authors note. As a result, they examined I-S1 uptake in male and female mice that expressed human APOE3 or APOE4 (induced by a mouse ApoE promoter).

Multiple-comparison tests showed that among male mice that expressed human APOE3, the "fastest I-S1 uptake" was in the olfactory bulb, liver, and kidney. Female mice displayed increased APOE3 uptake in the spleen.

"This observation might relate to the increased susceptibility of men to more severe COVID-19 outcomes," coauthor Jacob Raber, PhD, professor, Departments of Behavioral Neuroscience, Neurology, and Radiation Medicine, Oregon Health and Science University, Portland, Oregon, said in a press release.

In addition to intravenous I-S1 injection, the researchers also investigated the effects of intranasal administration. They found that although it also entered the brain, it did so at levels roughly 10 times lower than those induced by intravenous administration.

Banks said his laboratory has studied the BBB in conditions such as Alzheimer's disease, obesity, diabetes, and HIV.

"Our experience with viruses is that they do an incredible number of things and have a frightening number of tricks," he said. In this case, "the virus is probably causing inflammation by releasing cytokines elsewhere in the body that get into the brain through the BBB."

Conversely, "the virus itself may enter the brain by crossing the BBB and directly cause brain cells to release their own cytokines," he added.

An additional finding of the study is that whatever the S1 protein does in the brain is a model for what the entire virus itself does, because these proteins often bring the viruses along with them, he added.

Banks said the clinical implications of the findings are that antibodies from those who have already had COVID-19 could potentially be directed against S1. Similarly, he added, so can COVID-19 vaccines, which induce production of S1.

"When an antibody locks onto something, it prevents it from crossing the BBB," Banks noted.

Commenting on the study for Medscape Medical News, Howard E. Gendelman, MD, Margaret R. Larson Professor of Internal Medicine and Infectious Diseases and professor and chair of the Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, Nebraska, said the study is confirmatory.

"What this paper highlights, and we have known for a long time, is that COVID-19 is a systemic, not only a respiratory, disease involving many organs and tissues and can yield not only pulmonary problems but also a whole host of cardiac, brain, and kidney problems," he said.

"So the fact that these proteins are getting in [the brain] and are able to induce a reaction in the brain itself, and this is part of the complex progressive nature of COVID-19, is an important finding," added Gendelman, who is also the director of the Center for Neurodegenerative Disorders. He was not involved with the study.

The study was supported by the Veterans Affairs Puget Sound Healthcare System and by grants from the National Institutes of Health. The authors and Gendelman have disclosed no relevant financial relationships.

Nat Neurosci. Published online December 16, 2020. Full text

For more Medscape Psychiatry news, join us on Facebook and Twitter

See original here:
New Evidence COVID-19 Invades the Brain - Medscape

Cormac the Llama Yields Antibodies That May Prove Effective Against COVID-19 – Department of Defense

Researchers at the Uniformed Services University of the Health Sciences recently identified pint-sized antibodies, or "nanobodies," that could protect against COVID-19. At least one of these nanobodies produced by a llama named Cormacalso appears to work well in either liquid or aerosol form, suggesting it could also help protect a person's lungs from infections.

The study was led by Dr. David Brody, director of USU's Center for Neuroscience and Regenerative Medicine, along with Thomas J. "T.J." Esparza, a Henry M. Jackson Foundation for the Advancement of Military Medicine employee working in support of CNRM. Both Esparza and Brody also work in the National Institutes of Health's National Institute of Neurological Disorders and Stroke .

Nanobodies are a type of antibody naturally produced by the immune systems of camelids, such as camels, alpacas and llamas. These proteins are about a tenth of the weight of most human antibodies on average. They can be isolated in the lab and essentially free-floating versions of the tips of the arms of heavy chain proteins, which form the backbone of a typical Y-shaped human immunoglobulin antibody found in the blood. These tips recognize proteins on viruses, bacteria and other invaders, also known as antigens. Therefore, they play a vital role in the immune system's defenses.

Nanobodies are also more stable, less expensive to produce and easier to engineer than typical antibodies. Therefore, they have been increasingly used for medical research. A few years ago, for example, scientists showed humanized nanobodies may be more effective at treating an autoimmune form of thrombotic thrombocytopenic purpura, a rare blood disorder, than current treatments.

Since the pandemic broke, several researchers have produced llama nanobodies against the SARS-CoV-2 spike protein, which is believed to be effective at preventing infections. In this study, published in Scientific Reports, the researchers used a slightly different strategy to find nanobodies that may work especially well.

"For years, TJ and I had been testing out how to use nanobodies to improve brain imaging. When the pandemic broke, we thought this was a once in a lifetime, all-hands-on-deck situation and joined the fight,"Brody, the senior author of the study, said. "We hope that these anti-COVID-19 nanobodies may be highly effective and versatile in combating the coronavirus pandemic."

The researchers found that at least one of these nanobodies, called NIH-CoVnb-112, may be highly effective at preventing infections or detecting virus particles by grabbing hold of SARS-CoV-2 spike proteins. These "spike proteins" act like a key by "opening the door to infections" when they bind to a protein found on the surface of certain cells, called the angiotensin converting enzyme 2 receptor, the researchers explained. They then found a way to isolate these nanobodies that block infections by covering the "teeth" of the spike protein, which bind to and unlock the ACE2 receptor. This was done by immunizing the llama, Cormac, five times over the course of 28 days with a purified version of the SARS-CoV-2 spike protein.

After testing hundreds of nanobodies, they found Cormac produced 13 nanobodies that could potentially be strong candidates, including one they refer to as NIH-CoVnB-112. The researchers then showed that the NIH-COVnB-112 nanobody could be effective at preventing infections.

To mimic the COVID-19 virus, the researchers genetically mutated a harmless 'pseudovirus' so that it could use the SARS-CoV-2 spike protein to infect cells that produce human ACE2 receptors. The researchers saw that relatively low levels of the NIH-CoVnb-112 nanobodies prevented the pseudovirus from infecting these cells in petri dishes.

Additionally, the researchers showed that the nanobody was just as effective in preventing the infections in petri dishes when it was sprayed through a nebulizer, or inhaler, often used to help treat patients with asthma.

"One of the exciting things about nanobodies is that, unlike most regular antibodies, they can be aerosolized and inhaled to coat the lungs and airways," Brody said. "This is promising in that it could potentially be used to protect the lungs from infections."

This study was supported by NIH Intramural Research Programs at the National Institute of Neurological Disorders and Stroke and National Institute of Environmental Health Sciences.

Visit link:
Cormac the Llama Yields Antibodies That May Prove Effective Against COVID-19 - Department of Defense

Global Genetic Testing Market Forecasts for Applications and Technologies to 2025 – ResearchAndMarkets.com – Yahoo Finance

The "Genetic Testing. Global Market Forecasts for Applications and Technologies. Updated for COVID-19 Pandemic Impact with Executive and Consultant Guides 2021 to 2025" report has been added to ResearchAndMarkets.com's offering.

The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry.

The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry. The report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.

Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Companies Mentioned

10x Genomics, Inc

23andME Inc

Abbott Diagnostics

AccuraGen Inc

Adaptive Biotechnologies

Admera Health, LLC

Agena Bioscience, Inc

Agilent

Akonni Biosystems

Ancestry.com LLC

Anchor Dx

ArcherDx, Inc

ARUP Laboratories

Asuragen

Baylor Miraca Genetics Laboratories

Beckman Coulter, Inc

Becton, Dickinson and Company

BGI Genomics Co. Ltd

Bio-Rad Laboratories, Inc

Bio-Techne

Bioarray Genetics

Biocept, Inc

Biodesix Inc

BioFluidica

BioGenex

Biolidics Ltd

bioMerieux Diagnostics

Bioneer Corporation

Cancer Genetics

Caris Molecular Diagnostics

CellMax Life

Centogene

Chronix Biomedical

Circulogene

Clinical Genomics

And Many More Companies!

1. Introduction and Market Definition

1.1 Genetic Testing Definition in This Report

1.2 The Genomics Revolution

1.3 Market Definition

1.3.1 Revenue Market Size

1.3.1 Newborn Screening

1.3.2 Non Invasise Pregnancy Testing

1.3.3 Predictive

1.3.4 Oncology

Story continues

1.3.5 Direct to Consumer

1.3.6 Other Application

1.3.7 PCR

1.3.4 NGS

1.3.5 Cytogenetic

1.3.6 Other Technology

1.4 U.S. Medical Market and laboratory Testing - Perspective

1.4.1 U.S. Medicare Expenditures for Laboratory Testing

2. Market Overview

2.1 Market Participants Play Different Roles

2.1.1 Supplier/pharmaceutical

2.1.2 Independent lab specialized/esoteric

2.1.3 Independent lab national/regional

2.1.4 Independent lab analytical

2.1.5 Public National/regional lab

2.1.6 Hospital lab

2.1.7 Physician lab

2.1.8 DTC Lab

2.1.9 Independent Genetic Testing Lab

2.1.10 Audit Body

2.2 Genetic Tests -Types, Examples and Discussion

2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market

2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity

2.2.3 Newborn Screening

2.2.2 Diagnostic Testing

2.2.3 Carrier Testing

2.2.6 Predictive and Presymptomatic Testing

2.2.7 Pharmacogenomics

2.2.8 Forensic Testing

2.2.9 Parental Testing

2.2.10 Ancestral Testing

2.3 Industry Structure

2.3.1 Hospital's Testing Share

2.3.2 Economies of Scale

2.3.2.1 Hospital vs. Central Lab

2.3.3 Physician Office Lab's

2.3.4 Physician's and POCT

2.4 Market Shares of Key Genetics Players - Analysis

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Genetic Discoveries Creating New Diagnostic Markets

3.1.2 Aging Population a Boon for Diagnostics

3.1.3 Pharmacogenomics Drives Further Growth

3.1.4 Oncology and Liquid Biopsy Enter New Era

3.1.5 Fertility Practice Growth drives market

3.1.6 Direct to Consumer begins to break out

3.2 Factors Limiting Growth

3.2.1 Increased Competition Lowers Price

3.2.2 Lower Costs

More:
Global Genetic Testing Market Forecasts for Applications and Technologies to 2025 - ResearchAndMarkets.com - Yahoo Finance

Common Brain Malformation Affecting About 1 in 100 Children Traced to Its Genetic Roots – SciTechDaily

The lowest part of a childs brain is visible below the bottom of the skull in this MRI scan and shows evidence of a Chiari 1 malformation. Researchers at Washington University School of Medicine in St. Louis have shown that Chiari 1 malformation can be caused by variations in two genes linked to brain development, and that children with large heads are at increased risk of developing the condition. Credit: David Limbrick

Discovery could aid early screening, shed light on how Chiari malformation arises.

About one in 100 children has a common brain disorder called Chiari 1 malformation, but most of the time such children grow up normally and no one suspects a problem. But in about one in 10 of those children, the condition causes headaches, neck pain, hearing, vision and balance disturbances, or other neurological symptoms.

In some cases, the disorder may run in families, but scientists have understood little about the genetic alterations that contribute to the condition. In new research, scientists at Washington University School of Medicine in St. Louis have shown that Chiari 1 malformation can be caused by variations in two genes involved in brain development.

The condition occurs when the lowest parts of the brain are found below the base of the skull. The study also revealed that children with unusually large heads are four times more likely to be diagnosed with Chiari 1 malformation than their peers with normal head circumference.

The findings, published Dec. 21 in the American Journal of Human Genetics, could lead to new ways to identify people at risk of developing Chiari 1 malformation before the most serious symptoms arise. It also sheds light on the development of the common but poorly understood condition.

A lot of times people have recurrent headaches, but they dont realize a Chiari malformation is the cause of their headaches, said senior author Gabriel Haller, PhD, an assistant professor of neurosurgery, of neurology and of genetics. And even if they do, not everyone is willing to have brain surgery to fix it. We need better treatments, and the first step to better treatments is a better understanding of the underlying causes.

If people start experiencing severe symptoms like chronic headaches, pain, abnormal sensations or loss of sensation, or weakness, the malformation is treated with surgery to decompress the Chiari malformation.

Theres an increased risk for Chiari malformations within families, which suggests a genetic underpinning, but nobody had really identified a causal gene, Haller said. We were able to identify two causal genes, and we also discovered that people with Chiari have larger head circumference than expected. Its a significant factor, and easy to measure. If you have a child with an enlarged head, it might be worth checking with your pediatrician.

To identify genes that cause Chiari 1 malformation, Haller and colleagues sequenced all the genes of 668 people with the condition, as well as 232 of their relatives. Of these relatives, 76 also had Chiari 1 malformation and 156 were unaffected. The research team included first author Brooke Sadler, PhD, an instructor in pediatrics, and co-authors David D. Limbrick, Jr., MD, PhD, a professor of neurosurgery and director of the Division of Pediatric Neurosurgery, and Christina Gurnett, MD, PhD, a professor of neurologyand director of the Division of Pediatric and Developmental Neurology, among others.

Sequencing revealed that people with Chiari 1 malformation were significantly more likely to carry mutations in a family of genes known as chromodomain genes. Several of the mutations were de novo, meaning the mutation had occurred in the affected person during fetal development and was not present in his or her relatives. In particular, the chromodomain genes CHD3 and CHD8 included numerous variants associated with the malformation.

Further experiments in tiny, transparent zebrafish showed that the gene CHD8 is involved in regulating brain size. When the researchers inactivated one copy of the fishs chd8 gene, the animals developed unusually large brains, with no change in their overall body size.

Chromodomain genes help control access to long stretches of DNA, thereby regulating expression of whole sets of genes. Since appropriate gene expression is crucial for normal brain development, variations in chromodomain genes have been linked to neurodevelopmental conditions such as autism spectrum disorders, developmental delays, and unusually large or small heads.

Its not well known how chromodomain genes function since they have such a wide scope of activity and they are affecting so many things at once, Haller said. But they are very intriguing candidates for molecular studies, to understand how specific mutations lead to autism or developmental delay or, as in many of our Chiari patients, just to increased brain size without cognitive or intellectual symptoms. Wed like to figure out the effects of each of these mutations so that in the future, if we know a child has a specific mutation, well be able to predict whether that variant is going to have a harmful effect and what kind.

The association between chromodomain genes and head size inspired Haller and colleagues to measure the heads of children with Chiari malformations, comparing them to age-matched controls and to population averages provided by the Centers for Disease Control and Prevention. Children with Chiari tended to have larger than average heads. Those children with the largest heads bigger than 95% of children of the same age were four times more likely to be diagnosed with the malformation.

The findings suggest that children with larger heads or people with other neurodevelopmental disorders linked to chromodomain genes may benefit from screening for Chiari malformation.

A lot of kids that have autism or developmental disorders associated with chromodomain genes may have undiscovered Chiari malformations, Haller said. The only treatment right now is surgery. Discovering the condition early would allow us to watch, knowing the potential for serious symptoms is there, and perform that surgery as soon as its necessary.

Reference: Rare and de novo coding variants in chromodomain genes in Chiari I malformation by Brooke Sadler, Jackson Wilborn, Lilian Antunes, Timothy Kuensting, Andrew T. Hale, Stephen R. Gannon, Kevin McCall, Carlos Cruchaga, Matthew Harms, Norine Voisin, Alexandre Reymond, Gerarda Cappuccio, Nicola Burnetti-Pierri, Marco Tartaglia, Marcello Niceta, Chiara Leoni, Giuseppe Zampino, Allison Ashley-Koch, Aintzane Urbizu, Melanie E. Garrett, Karen Soldano, Alfons Macaya, Donald Conrad, Jennifer Strahle, Matthew B. Dobbs, Tychele N. Turner, Chevis N. Shannon, Douglas Brockmeyer, David D. Limbrick, Christina A. Gurnett and Gabe Haller, 21 December 2020, American Journal of Human Genetics.DOI: 10.1016/j.ajhg.2020.12.001

This study was funded by Sam and Betsy Reeves and the Park-Reeves Syringomyelia Research Consortium; the University of Missouri Spinal Cord Injury Research Program; the Childrens Discovery Institute of St. Louis Childrens Hospital and Washington University; the Washington University Institute of Clinical and Translational Sciences, grant number UL1TR000448 from the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH); the Eunice Kennedy Shriver National Institute of Child Health & Human Development, award number U54HD087011 to the Intellectual and Developmental Disabilities Research Center at Washington University; the Swiss National Science Foundation, grant number 31003A_182632; and the Jrme Lejeune Foundation.

Read more:
Common Brain Malformation Affecting About 1 in 100 Children Traced to Its Genetic Roots - SciTechDaily

Rare Genetic Variants in Immune Genes and Neonatal Herpes Simplex Viral Infections – American Academy of Pediatrics

Neonatal herpes simplex virus (HSV) infection is a devastating disease with high mortality, particularly when disseminated. Studies in adults and children suggest that susceptibility to herpes simplex encephalitis (HSE) may represent phenotypes for inborn errors in toll-like receptor 3 (TLR3) signaling. However, the genetic basis of susceptibility to neonatal HSV including disseminated disease remains unknown. To test the hypothesis that variants in known HSE-susceptible genes as well as genes mediating HSV immunity will be identified in neonatal HSV, we performed an unbiased exome sequencing study in 10 newborns with disseminated, HSE, and skin, eyes, and mouth disease. Determination of potential impact on function was determined by following American College of Medical Genetics and Genomics guidelines. We identified deleterious and potentially deleterious, rare variants in known HSE-related genes including a stop IRF3 variant (disseminated), nonsynonymous variants in TLR3 and TRAF3 (HSE), STAT1 (skin, eyes, and mouth), and DBR1 (disseminated) in our cohort. Novel and rare variants in other immunodeficiency genes or HSV-related immune genes GRB2, RAG2, PRF1, C6, C7, and MSR1 were found in 4 infants. The variant in GRB2, essential for T-lymphocyte cell responses to HSV, is a novel stop variant not found in public databases. In this pilot study, we identified deleterious or potentially deleterious variants in TLR3 pathway and genes that regulate anti-HSV immunity in neonates with HSV including disseminated disease. Larger, definitive studies incorporating functional analysis of genetic variants are required to validate these data and determine the role of immune genetic variants in neonatal HSV susceptibility.

Read more:
Rare Genetic Variants in Immune Genes and Neonatal Herpes Simplex Viral Infections - American Academy of Pediatrics

Richard Foley, a GOP chief who taunted the FBI, dies at 71 – The CT Mirror

Marty Heiser Show

From left, J.R. Romano, Dave Mathus, Matt OBrien and Richard Foley during the 2019 campaign for GOP chair.

On his way to prison in January 1994, the 44-year Richard Foley said he knew how his obituary would begin: There would be a mention of his service as a state lawmaker and Republican state chairman, followed by the fact he was convicted of taking a bribe.

Dick Foley wasnt known for flinching. He was the blue-collar guy who led the state GOP from 1989 to 1992, when Connecticut was a presidential swing state and the party struggled to decide if its future was in Fairfield County or the post-industrial Naugatuck Valley.

When it became clear in late 1992 that he was in the crosshairs of the FBI, Foley called a press conference to call the feds bumblers and bureaucrats. Were going on offense. Put up or shut up, Foley said. They picked on the wrong mick.

The quote ended up on the wall of a semi-secret office the FBI kept for a time in Waterbury, a corruption target. Foley was convicted of four felonies in connection with $25,000 he accepted from two corrupt businessmen, a developer and a banker.

When asked for an interview before he left for prison, Foley said, Yeah, why not?

Foley, 71, was found dead at his condominium in Danbury on Saturday. His friend, Ben F. Proto, said Foleys daughter called with news of his death. No cause was immediately evident.

He came head-on at pretty much everything, from politics to prison. He had an Irish memory, forever remembering friends and foes. He was a state representative, a salesman and a student of human behavior.

His conviction was overturned on appeal, and Foley managed a second act in political life as a lobbyist and campaign consultant. He attempted a comeback last year, challenging J.R. Romano for state chair of the GOP.

He won and lost plenty of political bets. In 1991, he was convinced that passage of the income tax by a Democratic legislature and an independent governor, Lowell P. Weicker Jr., would be the GOPs ticket to the majority. It wasnt.

I talked with him earlier in the week, said Proto, who joined Foley in the 2018 floor fight at the GOP state convention that led to Steve Obsitnik of Westport obtaining enough delegate support to join the party primary for governor. We were going to have lunch next week. He was a dear friend. He was the kind of guy you wanted to have as a friend.

Proto said that Foley was steeped in Connecticuts political history and was among the very young Republicans who, in the early 1970s, made up Gov. Thomas Meskills kiddie corps.

Chris Healy, a former GOP state chairman, said Foley prized and exuded loyalty.

He was the most-loyal, steadfast person you could find, Healy said Saturday. I am grief-stricken because I lost one of my best friends. You either loved him or hated him, and those of us who loved him, we would have done anything for him. He loved to have fun, and he loved to laugh at the absurdity of things. You always ended up laughing during a conversation with Dick Foley, at some point.

MSNBC

Richard Foley

Foley was blunt, often coarse. He had no patience for the timid or cautious. To them, he would say, If you want a guarantee, then buy a f refrigerator.

He could be flippant, but his advice to candidates seeking counsel on issues of morality was not: figure out where you stand; dont be cute; your constituents will tolerate a principled difference.

He offered himself as an example. For 10 years, he represented a conservative and largely Catholic district, but he was more pro-choice than pro-life in his voting.

His legal troubles came from an association with Richard D. Barbieri Sr. and John A. Corpaci, key figures in a Waterbury corruption scandal. They told the FBI they had built a favor bank with politicians as they established a real estate and banking business.

To curry favor with a bigger banking chain, they said they paid Foley $25,000 to help pass a bill liberalizing state banking laws. The story had some holes: Foley, for one, was in the minority. Second, he voted against the bill and urged its defeat.

Foley never denied accepting ten $2,500 payments, but he insisted they were a consulting fee in return for seeking tenants for a commercial property. He was convicted and sentenced to 40 months in prison.

He went to prison uncertain about winning his appeal.

Over coffee at an Abdows Big Boy on the Silas Deane Highway in Wethersfield, Foley talked for three hours about prison and his expectation he might have to serve three years before qualifying for a good-behavior release.

He smoked a cigar, one that he promised would be among his last. He was loud. An elderly woman in the next booth gave him a long sideward glance, mouth agape.

Foley talked about quitting tobacco, losing weight. If he was going to lose three years going in, perhaps he could gain five more on the back end by clean living.

But he had no illusions about how he would be remembered, even if he won his appeal.

In most situations, death pays the debt. Not in this one, he said. This one you pay after you die. Thats hard. Thats hard. But thats one you gotta accept. Thats the way its going to be.

A federal appeals court voted 2-1 in January 1996 to overturn his conviction, concluding he had been improperly charged under statutes that covered the illegal acceptance of federal funds.

Foley served four months in prison, then was freed on bond during his appeal.

Ken Dixon of Hearst Media contributed to this report.

See more here:
Richard Foley, a GOP chief who taunted the FBI, dies at 71 - The CT Mirror

Alexandra Ziesler: Trump was the right president at the right time – Salt Lake Tribune

(Susan Walsh | AP photo)In this Nov. 20 photo, President Donald Trump listens during an event in the briefing room of the White House in Washington.

By Alexandra Ziesler | Special to The Tribune

| Jan. 3, 2021, 1:00 p.m.

It takes courage to face the onslaught of daggers and arrows that come as people are forced to leave behind whats familiar, no matter how dysfunctional. Yet familiar patterns, established ways, even traditions can evoke complacency, ingratitude, boredom, sluggishness. It can take the force of immense moral courage to break these holds to awaken to new freedom.

At the eve of a new presidential administration, I want to thank President Trump for his example of morally courageous leadership. He forced a fresh look at everything from news gathering practices to domestic policy, from business practices to foreign relations. His fearless defense of our country and insistence that we use a new type of logic one that questions the rationale of past decisions brought purpose to many.

Beyond policy reform, he enlivened the human spirit to reengage in the national discourse and fight for Americas well-being. He stirred things up enough to allow us to see societal problems and begin conversations we had avoided for years. His brazenness gave us space to be less afraid of the ugliest of human behavior in ourselves and others we couldnt escape confrontation with it and that made larger issues less intimidating.

He was the right president at the right time. Withstanding hate and fear, he helped us leave old ways of doing things. When waking people from complacency, apathy and depression, kind words arent always effective. His election seemed a call to the spirit of those who were ready to recognize their own power, ask questions and employ the moral requirement of being an alert, engaged and informed citizen.

With freedom comes responsibility. During his presidency, he demonstrated this responsibility, following words up with actions. He engaged dialog with foreign dignitaries, who many called enemies. Somehow, they dont feel like enemies anymore.

Under Trumps administration, subversive tactics from North Korea and Russia lessened. Looking at his approach, Trumps genuine discourse with those countries leaders people who need love and attention just like the rest of us seemed to meet the spiritual needs and still historical patterns of aggressiveness.

What if, beyond the torrent of Trumps mean-sounding words and brash bravado, we could have recognized his use of moral courage, bringing healing between nations?

The highlight of his presidency, for me, was the refusal to engage in military action against Iran. In late 2018, there were provocations and his advisors advocated a strong military response. Yet, Trump had the discipline to counsel with his sense of moral justice and drew a line that would only be crossed if there had been a direct hit to an American. There was a response, but no war.

While the legacy of Trump may be long-debated, we may all be cheering if we were to look at Americas progress from a psychological perspective. To me, a quake-like wrenching has taken place, replacing complacency with vigor. What if Trump has led us through a national re-awakening? Even media pundit George Stephanopoulos acknowledged on election night 2020, that Trumps legacy is a more engaged electorate.

Trump incited us to care again, to engage, to consider how and where to take action. Care, action, engagement are tools of love. He brought national focus back to ourselves, allowed us to build from within, strengthen Americas sense of self. Any psychologist would applaud this approach for a patient.

Our country is maturing. No matter who the president is, each of us has the moral duty to engage with each other productively, purposefully, and harmoniously. We have a long way to go, but there is new momentum now.

Thank you, President Trump.

Alexandra Ziesler, Park City, studies the Science of Spirit and practices through her business, The Truth of Being.

Read this article:
Alexandra Ziesler: Trump was the right president at the right time - Salt Lake Tribune